Pfizer inc (PFE)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Apr'18Dec'17Oct'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Dec'10Sep'10Jun'10Mar'10Dec'09Sep'09Jun'09Mar'09
Operating Activities
Net income before allocation to noncontrolling interests

3,410

-326

7,683

5,056

3,889

-383

4,122

3,879

3,570

12,289

2,858

3,078

3,130

781

1,354

2,063

3,048

-169

2,138

2,636

2,381

1,236

2,673

2,921

2,338

2,574

2,599

14,134

2,765

6,321

3,214

3,260

1,803

1,448

3,749

2,618

2,234

2,897

871

2,485

2,035

766

2,881

2,266

2,730

Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:
Depreciation and amortization

1,218

1,384

1,553

1,528

1,545

1,641

1,614

1,562

1,567

1,574

1,566

1,574

1,555

1,549

1,396

1,387

1,425

1,424

1,272

1,201

1,260

1,331

1,326

1,424

1,456

1,489

1,521

1,626

1,774

2,107

1,656

1,671

2,221

2,458

2,215

2,249

2,104

1,906

2,229

2,213

2,051

1,774

969

1,006

1,008

Asset write-offs and impairments

45

2,729

46

23

155

3,310

47

34

7

308

229

62

35

467

163

837

146

255

822

31

11

117

225

52

137

237

260

135

513

434

107

108

650

425

200

391

182

530

2,123

774

59

-

-

-

-

TCJA impact

0

-4

-34

-154

-131

-186

-342

0

-68

-10,660

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain on completion of Consumer Healthcare JV transaction, net of cash conveyed

6

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Acquisition-related in-process research and development charges

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

74

-

-

-

-

Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal

-

-

-

-

-

-

-

-

-

-

12

-27

-37

-290

-1,422

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain associated with the transfer of certain product rights to an equity-method investment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

918

31

-490

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred taxes from continuing operations

109

-1,453

2,227

-100

-60

-1,231

-474

-794

294

-2,651

-79

282

38

635

-1,325

194

-204

145

18

-142

-41

-446

-87

508

345

59

413

334

920

656

256

270

-396

-457

188

625

-120

832

-333

770

840

-10,711

390

198

533

Deferred taxes from discontinued operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-4

-26

7

1,422

-30

28

-8

-

-

-

-

-

-

-

-

-

-

-

-

Share-based compensation expense

64

270

64

199

185

267

303

197

182

245

207

170

218

159

145

244

143

181

141

185

162

162

143

138

143

105

126

103

189

119

115

117

130

72

103

122

122

54

108

105

138

91

89

98

71

Benefit plan contributions in excess of expense/income

248

-93

116

162

151

95

174

134

692

-81

-37

93

986

-63

-82

4

853

-187

-38

-32

874

-9

84

25

99

-54

-391

78

71

-221

106

45

-65

-1,499

-21

134

-383

29

-940

71

163

-

-

-

-

Other adjustments, net

-123

464

160

226

236

99

647

362

161

-1,003

146

233

225

-419

102

59

-229

-32

-10

-142

336

-34

165

5

294

220

-139

-18

119

12

4

86

28

-111

103

-29

19

-184

43

352

-260

49

44

4

-296

Other changes in assets and liabilities, net of acquisitions and divestitures:
Other changes in assets and liabilities, net of acquisitions and divestitures

1,581

-

-1,480

3,553

3,498

-

-809

535

2,715

-

-228

1,627

2,217

-

-1,600

1,057

2,125

-

-582

-4

1,883

-

-430

858

1,091

-

-715

2,137

3,327

-

417

1,392

1,533

-

361

263

-522

-

-2,659

1,193

11,980

-

593

-652

899

Net cash provided by operating activities

3,133

3,769

4,510

2,611

1,698

4,738

5,259

3,847

1,983

7,089

4,889

3,240

1,584

6,041

4,737

3,606

1,808

4,898

5,020

4,090

680

5,599

4,463

4,087

2,935

5,724

5,900

3,757

2,303

4,948

5,003

4,021

2,774

5,261

4,439

5,898

4,642

6,258

6,683

4,873

-6,360

4,825

4,101

4,514

3,147

Investing Activities
Purchases of property, plant and equipment

463

672

565

479

460

685

547

424

386

700

450

448

358

689

432

401

301

611

289

258

239

354

275

278

292

417

278

309

202

494

285

294

254

598

454

358

250

547

288

373

305

422

261

269

253

Purchases of short-term investments

2,551

2,252

520

2,661

1,402

4,313

4,242

2,209

913

8,127

4,075

1,693

701

787

6,426

5,255

3,489

7,513

5,039

8,483

7,546

14,660

15,213

12,360

8,721

8,834

12,264

10,921

10,742

9,431

4,192

4,051

6,344

4,990

6,898

3,207

3,352

6,064

1,487

1,353

2,178

-21,817

18,248

21,176

17,724

Proceeds from redemptions/sales of short-term investments

3,257

1,417

1,765

2,400

3,601

4,829

2,255

4,034

6,463

4,524

2,261

1,285

2,232

8,729

5,928

6,835

7,922

6,455

13,126

9,781

10,702

14,491

12,088

13,226

7,569

12,119

14,506

8,116

6,386

5,925

5,020

6,238

8,119

6,955

2,578

2,090

2,553

-3,794

-1,555

-340

11,388

10,617

17,496

7,540

6,711

Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less

416

1,382

-3,590

1,224

-5,941

4,302

846

3,276

-4,507

700

666

354

-3,778

10,703

-6,734

742

-493

-211

-2,537

2,223

-5,243

1,015

-3,546

101

-1,500

2,100

1,776

-5,195

5,596

24

-2,482

1,622

-623

-226

-2,321

-2,344

-5,983

-

-

-

-

-

-

-

-

Purchases of long-term investments

22

67

11

39

84

294

433

465

605

1,011

863

923

740

3,240

1,645

1,818

1,308

2,964

1,156

2,272

3,150

1,464

3,927

3,519

1,808

2,274

3,513

2,987

2,246

2,451

6,377

1,133

1,184

974

453

1,261

1,932

1,454

1,193

623

858

835

787

1,824

3,442

Proceeds from redemptions/sales of long-term investments

152

116

-26

98

44

4,070

813

785

576

1,176

865

694

844

4,353

4,488

1,285

1,142

2,394

1,244

1,354

1,937

1,508

1,690

1,493

1,454

1,612

2,749

1,750

1,444

1,633

3,053

2

302

146

429

684

888

915

666

2,029

1,127

1,680

1,340

2,595

889

Payments to Acquire Businesses, Net of Cash Acquired

-

-

-

-

-

-

-

-

-

0

0

415

585

689

13,063

4,506

110

144

15,643

1

678

0

195

0

0

-

-

-

-

268

0

0

782

94

19

0

3,169

-

-

-

-

-

-

-

-

Acquisitions of intangible assets

32

54

97

109

158

107

15

0

32

-

-

-

-

-

-

-

-

51

36

5

7

42

286

50

6

82

50

1

126

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other investing activities, net

-4

-60

34

-112

-67

-40

-110

-81

-57

-152

-64

-158

-297

-20

-34

-20

-6

2

-13

-3

-330

-22

-37

-82

-206

-118

-23

-15

-156

-189

-52

27

29

-93

-335

-69

-4

378

23

-299

-220

408

-162

-161

-185

Net cash provided by/(used in) investing activities

-71

-2,833

-6,760

-1,902

7,550

-764

-2,904

-1,474

9,667

-4,759

-3,011

-1,738

4,768

-3,087

-4,381

-4,678

4,355

-2,224

-5,243

-2,105

6,592

-1,514

-2,535

-1,507

-98

142

-603

843

-10,926

6,837

-247

-887

451

542

215

361

725

-5,645

-3,880

-361

9,394

-4,367

-298

-12,973

-13,634

Financing Activities
Proceeds from short-term borrowings

5,302

4,873

7,626

3,347

609

1,766

199

1,318

428

1,461

2,204

2,245

2,554

1,075

4,090

1,625

682

3,535

0

23

1,999

5

7

1

0

600

1,389

1,303

1,031

2,295

1,936

2,203

1,561

3,197

4,745

2,186

2,682

1,714

1,517

1,277

1,892

2,686

6,719

10,980

10,774

Principal payments on short-term borrowings

7,551

4,290

1,713

609

1,766

198

1,318

428

2,493

2,288

2,571

2,569

2,519

1,772

1,030

941

1,350

3,949

5

11

0

7

-4

4

3

458

1,443

1,302

1,031

-

-

-

-

9,450

1,343

847

1,636

-16

1,944

3,658

3,663

4,993

7,483

10,393

12,100

Net proceeds from short-term borrowings with original maturities of three months or less

3,207

-53

-115

687

2,032

-644

-3,065

2,175

-83

856

301

2,375

-2,110

-2,097

-3,145

458

1,724

810

1,426

-382

863

917

-66

-3,723

1,031

1,644

-420

-1,234

3,485

146

173

1,442

-1,791

8,153

-3,791

-1,868

-584

-

-

-

-

-

-

-

-

Proceeds from issuance of long-term debt

1,241

0

0

0

4,942

0

4,974

0

0

1

0

0

5,273

5,945

0

5,031

0

-

-

-

-

-

-

-

-

0

0

3,994

2,624

0

0

0

0

-

-

-

-

-

-

-

-

26

1

10,604

13,392

Principal payments on long-term debt

2,181

1,000

451

2,351

3,004

462

0

2,749

355

1,680

1

3,220

1,253

3,372

0

2,781

1,536

-4

-1

-3

2,998

1,324

34

0

752

1,750

2

2,392

2

1,499

7

4

3

3,500

5

-397

3,878

2

2

-7

9

57

2

605

303

Purchases of common stock

0

0

0

0

8,865

5,030

1,105

0

6,063

0

0

0

5,000

0

0

0

5,000

0

160

0

6,000

1,199

1,281

1,323

1,197

4,647

3,754

3,263

4,626

3,394

1,835

1,340

1,659

3,211

2,110

2,249

1,430

-

-

-

-

-

-

-

-

Cash dividends paid

2,105

1,992

2,004

2,002

2,045

1,963

1,994

1,989

2,032

1,909

1,895

1,910

1,945

1,821

1,821

1,821

1,854

1,729

1,728

1,725

1,758

1,639

1,650

1,658

1,662

1,554

1,590

1,701

1,735

1,619

1,632

1,633

1,650

1,524

1,551

1,568

1,591

1,544

1,549

1,554

1,441

1,280

1,068

1,067

2,133

Proceeds from exercise of stock options

124

91

55

122

126

160

625

102

372

206

245

98

313

73

250

400

296

98

184

187

794

298

121

158

425

380

195

533

642

213

157

163

35

-

-

-

-

-

-

-

-

-

-

-

-

Other financing activities, net

-237

-69

-126

-46

-495

-35

278

-336

-495

-388

5

-8

-220

-344

-6

-54

-132

-62

17

32

122

-179

13

18

25

41

-6

28

46

-

-

-

-

-68

20

31

33

34

-45

67

10

10

5

-111

5

Net cash used in financing activities

-2,200

-2,440

3,273

-851

-8,467

-6,407

-1,406

-1,908

-10,720

-3,743

-1,711

-2,989

-4,907

-2,313

-1,662

1,918

-7,171

-1,294

-263

-1,874

-6,978

-3,127

-2,887

-2,040

-2,133

-5,744

-5,631

-4,034

434

-6,233

-3,291

-2,968

-3,507

-6,250

-4,035

-3,918

-6,404

-1,079

-2,523

-4,361

-3,211

-2,734

-1,828

9,408

9,635

Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents

-15

9

-13

-40

12

0

-101

-70

55

-14

30

16

21

-136

-11

5

-73

-838

-84

-4

-74

-53

-9

4

-25

9

-50

-22

0

23

10

-69

34

-77

-9

25

32

25

19

-33

-42

20

15

48

-23

Net increase in cash and cash equivalents and restricted cash and cash equivalents

846

-1,495

1,008

-180

792

-2,432

846

396

985

-1,428

198

-1,470

1,465

506

-1,317

850

-1,080

542

-571

107

220

905

-968

544

679

131

-384

544

-8,189

5,575

1,475

97

-248

-524

610

2,366

-1,005

-441

299

118

-219

-2,256

1,990

997

-875

Receipt of ICU Medical common stock

-

-

-

-

-

-

-

-

-

0

0

0

428

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Promissory note from ICU Medical

-

-

-

-

-

-

-

-

-

0

0

0

75

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Exchange of subsidiary common stock (Zoetis) for the retirement of Pfizer commercial paper issued in 2013

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

2,479

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Exchange of subsidiary senior notes (Zoetis) for the retirement of Pfizer commercial paper issued in 2012(b)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

992

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Transfer of certain product rights to an equity-method investment (Hisun Pfizer)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

1,233

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Income taxes

239

1,028

500

1,901

235

1,989

469

940

257

1,065

303

926

195

1,091

319

593

518

969

290

752

372

616

416

532

536

1,075

494

757

548

514

768

676

451

1,388

802

871

-134

256

208

764

10,547

552

639

655

454

Interest paid

472

341

437

424

385

343

244

465

259

417

220

665

216

274

274

494

409

140

248

582

332

221

333

635

361

217

409

670

433

198

481

686

508

213

535

650

687

116

697

550

792

212

424

215

84

Interest rate hedges

-11

36

-6

-39

-33

66

-33

-91

20

-16

43

-258

32

18

-50

-279

-27

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-